Sells BRIUMVI, a medicine for adults with relapsing multiple sclerosis, and develops other treatments for diseases involving B cells.
10-K for FY2025, filed Feb 27, 2026
TG earns revenue mainly from BRIUMVI product sales, counted when delivered. Its agreement with Neuraxpharm also provides upfront and milestone payments and royalties on sales.
10-K for FY2025, filed Feb 27, 2026
10-K for FY2025, filed Feb 27, 2026
FY2025 revenue by product or service ↗$616.3M
10-K for FY2025, filed Feb 27, 2026
$616.3M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
10-K for FY2025, filed Feb 27, 2026 |
98%
FY2022: 95%
|
Product, FY2025
$606.9M Sources
|
Sold outright |
|
License Revenue
Licensed
|
<0.1%
FY2022: 5.5%
|
License Revenue, FY2025
$152K Sources
|
Licensed |
|
Milestone
|
0.0% |
Milestone, FY2025
$0 Sources
|
|
|
Royalty
Licensed
|
0.9% |
Royalty, FY2025
$5.6M Sources
|
Licensed |
|
Other Revenue
|
0.6% |
Other Revenue, FY2025
$3.6M Sources
|
TG sells BRIUMVI mainly through specialty distributors; outside the U.S., Neuraxpharm commercializes the product under an agreement.
10-K for FY2025, filed Feb 27, 2026
Yes. It kept 73 cents of every revenue dollar as net income in FY2025, but spent more cash than it brought in: free cash flow was −$25M.
10-Q for Q3 FY2026, filed Nov 9, 2026
$55.5MView ↗
10-Q for Q3 FY2026, filed Nov 9, 2026
Open tableView ↗
8-K, filed Nov 9, 2026
Raises full-year 2026 total global revenue guidance to approximately $1 billion, from approximately $950 millionView ↗
Growing. Revenue grew 92.1x in 4 years, from $6.7M in FY2021 to $616.3M in FY2025, about 210% a year.
International commercialization
The earlier report described BRIUMVI's U.S. approval and launch; the latest report also describes approvals outside the U.S. and an agreement for commercialization beyond the U.S.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 27, 2026
Competes with Roche Holdings and Novartis
10-K for FY2025, filed Feb 27, 2026Currently, BRIUMVI directly competes with ocrelizumab, the only other approved intravenously administered anti-CD20 monoclonal antibody…View ↗
Loading...